 Med. 2006;48: 489 -496) 
L ead distributes in the body into three pools: blood, soft tissue, and bone. Because the characteristic residence time of lead in the blood is approximately 30 days, blood lead is primarily an estimate of recent dose, but is also in equilibrium with bone lead stores. 1 With the development of x-ray fluorescence (XRF) systems, lead levels in bone have been easier to obtain. Tibia lead, representative of cortical bone, has a residence time of 25 to 30 years and serves as a biomarker of cumulative dose. 2 Trabecular bone lead is measured at sites such as the patella, calcaneus, and finger. The clearance of lead from the patella is characterized by more complex kinetics; some authors have identified two or three phases of elimination with clearance half-times ranging from months to years. 3, 4 Thus, lead in the patella is often considered to be a biomarker of bioavailable lifetime dose that encompasses aspects of both accumulation and short-term bioavailability. 5 Studies that contrast associations of health effects with different lead biomarkers that estimate pools of lead with varying kinetics and bioavailability can assist with causal inference and help interpret the conflicting evidence in the published literature. For example, two recent meta-analyses have been published, which have evaluated the association of moderate blood lead levels and neurobehavioral test scores. Both analyses attempted to make inferences about the cognitive effects of lead around blood lead levels of 70 g/dL because of proposed changes *In a population of lead workers from a secondary smelter, 38 men were divided into two subgroups based on their bone-lead concentration. High-and low-level individuals were matched to each other and an unexposed control on age, education, and job level. Lead exposure was assessed by bone lead measurements, current blood lead, the highest lead level ever measured in the individual, and the cumulative blood lead index (product of current blood lead level and duration of employment). Neuropsychologic testing and self-rating scales for psychiatric symptoms were performed.
†Fifty-four lead storage battery workers were divided into two subgroups based on maximum prior blood lead levels. If blood lead had not exceeded 2.4 mol/L, the individual was placed in the low blood lead maximum group. Assessment of lead exposure based on medical surveillance data at the plant. Cumulative exposure was assessed by time-weighted average, maximum blood lead, and integration of the cumulative dose of blood lead over duration of exposure. Calcaneal and tibia lead levels were also measured. Neuropsychologic testing and mood and symptom rating were performed.
‡Men from the VA Normative Aging Study who were evaluated between April 1993 and March 1994 were eligible for the study and included if they had data available on blood lead level, bone lead measurements, and cognitive test results. Lead exposure was assessed by blood lead, tibial lead, and patella lead measurements. Neurocognitive testing was performed.
§Men from the VA Normative Aging Study who had their first bone lead visit between January 1, 1991, and December 31, 1995, were eligible for participation provided bone lead measures were obtained within 3 mo of completing the Brief Symptom Inventory (BSI). Blood, tibia, and patella lead levels are reported. The outcome of interest was psychiatric symptoms as assessed by the BSI.
Participants in the VA Normative Aging Study who agreed to undergo cognitive testing also completed the Mini-Mental Status Examination. Those who also underwent bone lead measurement were included in the study.
¶Men from the VA Normative Aging Study who had at least two Mini-Mental Status Examinations and bone lead measurements available were included. The study was designed to investigate longitudinal decline in scores for tests completed on average 3.5 yr apart. **Median (range). † †mol/L. ‡ ‡g Pb/g bone mineral mean (range). § §From Hu H, Payton M, Korrick S, et al. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. Am J Epidemiol. 1996;144:749 -759.ˆA ll studies were completed using subjects from the VA Normative Aging Study. ¶ ¶95% confidence interval. ***Mean (interquartile range). SD indicates standard deviation; NBT, neurobehavioral testing; OR, odds ratio; MMSE, mini-mental status examination.
in lead regulations in Germany. 6, 7 Meyer-Baron and Seeber concluded that blood lead levels of approximately 40 g/dL were associated with deficits in neurocognitive function. 6 In contrast, Goodman et al, in an analysis supported by the German lead industry, concluded that the data available were insufficient and inconsistent to make conclusions about the neurobehavioral effects of lead at blood lead levels less than 70 g/dL.
7 Inferences regarding cumulative dose have been addressed by Balbus-Kornfeld et al who reviewed 21 studies to determine if cumulative exposure to lead was associated with chronic neurobehavioral dysfunction and concluded that there were no studies that had adequately addressed the question. 8 Since that review, several studies have examined relations of tibia lead, a biomarker of cumulative lead dose, with neurobehavioral test scores, but conclusions have been inconsistent across studies. 9 -14 Six studies have examined associations of trabecular bone lead with neurobehavioral test scores. 10 -12,15-17 Study design, study populations, neurobehavioral outcomes, and conclusions have varied across studies (Table  1) . Two studies were conducted in occupationally exposed individuals; Ö sterberg 10 measured finger bone lead in 38 Swedish workers and Hänninen 11 investigated calcaneus bone lead in 54 Finnish workers. Relations between trabecular bone lead and neurobehavioral function were not strong and were not consistent across the two studies.
In studies of the population reported here, we have reported that blood lead was a better predictor of neurobehavioral test scores at crosssection than was tibia lead. 18 In longitudinal analyses, blood lead levels were associated with baseline test scores; change in blood lead levels was associated with change in test scores, and tibia lead was associated with test score declines over time. 19 Now, we present relations of patella lead with neurobehavioral test scores and compare those relations with those obtained for blood lead and tibia lead in the 652 Korean inorganic lead workers who completed patella lead measurement. To our knowledge, this is the largest study of occupational lead exposure that has evaluated relations of different lead biomarkers with cognitive function.
Materials and Methods

Study Overview and Design
The results presented in this report are from a cross-sectional analysis of data from the third year of a 3-year longitudinal study of Korean lead Calcaneus lead levels were associated with symptoms (P Ͻ 0.05) in the low blood lead group. Decline in test scores in one of 13 tests for calcaneus and three of 13 for blood lead. workers. The study aims, population, and design have been previously described 18 -23 ; in brief, 803 leadexposed workers and 135 control subjects were enrolled between October 24, 1997, and August 19, 1999 . For this report, the 652 lead-exposed workers who completed the third visit-the visit during which patella lead levels were measured-were included. The study was reviewed and approved by the Institutional Review Boards at the Johns Hopkins School of Hygiene and Public Health (Baltimore, Maryland) and the Soonchunhyang University School of Medicine (Chonan, South Korea).
Study Population
Lead-exposed workers were recruited from 26 facilities. Participation was voluntary and subjects received approximately $30 for their participation. Written informed consent was obtained from each subject. Participation was Ͼ80% in all but four of the sites. Because of plant closings during the study, 200 individuals at the third study visit were no longer working in lead-exposed jobs.
Data Collection
Detailed descriptions of the data collection procedures have been previously published. 18 -23 In brief, study participants completed a standardized interview and neurobehavioral test battery; blood pressure measurements were made; venipuncture was performed; and a urine sample was obtained. Tibia lead levels were measured at visits 1 and 2, patella lead at visit 3, and blood lead levels at all three visits. The details of the neurobehavioral testing have been presented elsewhere 18, 19 but, in brief, consisted of 14 neurobehavioral tests in six cognitive domains, four peripheral nervous system (PNS) measures and one measure of psychiatric symptoms. Test scores were reviewed by a neuropsychologist before modeling and scores not thought to be physiologically plausible were excluded from the analysis. 18 
Laboratory Methods
Blood lead levels were measured using a Zeeman background-corrected atomic absorption spectrophotometer (model Z-8100; Hitachi Ltd., Tokyo, Japan). 24 Tibia and patella lead were measured in micrograms of lead per gram of bone using 109 Cd-induced K-shell x-ray fluorescence (XRF) using previously reported methods. 18 -23 Thirty-minute measurements were taken from the left midtibia shaft and the left patella.
Statistical Analysis
The primary goals of the analysis were to: 1) evaluate associations of patella lead levels with neurobehavioral test scores, measures of PNS function, and the psychiatric symptom measure; and 2) to compare patella lead with tibia lead and blood lead in their associations with test scores. Linear regression modeling was used to evaluate associations between the lead biomarkers and test performance. The outcomes were standardized so that a higher test score always indicated better performance. The 19 outcomes were modeled separately for each biomarker. Age, gender, and education were controlled for in all models. In addition, when modeling the PNS sensory outcomes, height was included in the models, and for the PNS motor outcomes, body mass index was included. 18, 19 Additional covariates that were not significant predictors of test scores nor confounders of the relations between lead variables and test scores were not retained in the models. These covariates included tobacco use, alcohol consumption, former versus current lead exposure, type of lead-using facility, blood lead adjusted for hematocrit, and quadratic terms for the lead biomarkers (for assessment of nonlinear relations).
Patella, blood, and tibia lead were modeled nonparametrically (as percentiles after ranking) to account for extreme deviations from normality for the patella lead measurements and to allow for the magnitude of relations to be compared among the three biomarkers. Blood lead measurements for visit three and tibia lead measurements obtained at visit two on 574 study participants were used for the analysis. The following models were evaluated: (model 1) blood lead, tibia lead, or patella lead alone; (model 2) blood lead and tibia lead or blood lead and patella lead; (model 3) blood lead and job duration, mean tibia lead and job duration, or patella lead and job duration; and (model 4) blood lead, tibia lead, and job duration or patella lead, blood lead, and job duration. To simplify presentation of results, only those from model 3 are presented but the results of the other models are discussed. Model 3 was chosen for comparison because it includes job duration, which was previously shown to merit inclusion in the final models because it strengthened the relations with tibia lead levels, thought to be due to possible selection bias and dropout among workers with higher tibia lead levels. 18 Preliminary analysis of the patella lead levels revealed a wide range of values and nonnormality, and inferences regarding the associations with test scores were influenced by outliers. Examination of added variable plots of the residuals of patella lead versus neurobehavioral test scores confirmed that these models did not meet the assumptions for use of linear regression modeling. After transformation, examination of models with ranked patella in added variable plots supported use of ranked patella for these models.
In addition to presenting adjusted regression lines, the lowess smoothing function was used to make estimations of the associations of lead biomarkers to neurobehavioral test scores. 25 
Results
Demographic Data and Dose Measures
For the 652 current and former lead workers, the mean (standard deviation [SD]) age was 43.3 (9.6) years and mean job duration was 10.0 (6.5) years ( Table 2 ). The mean (SD) levels for the lead biomarkers were 30.9 (16.7) g/dL, 75.1 (101.1) g/g, and 33.6 (43.4) for blood lead (visit 3), patella lead (visit 3), and tibia lead (visits 2), respectively.
When compared with subjects who did not complete visit three, there were significant differences in age and job duration. Visit three noncompleters were younger 37.8 (11.4) years (P Ͻ 0.01) and had a shorter duration of employment (mean job duration of 6.6 [6.7] years) (P Ͻ 0.01). There were no differences in blood lead levels between completers and noncompleters (P ϭ 0.69). Tibia lead was highly correlated with patella lead levels (Pearson's r ϭ 0.89 and Spearman's r ϭ 0.76); the correlation of patella lead and blood lead was lower (Pearson's r ϭ 0.53 and Spearman's r ϭ 0.66). As patella lead levels increase, the relation with blood lead levels plateaus (Fig. 1) , as demonstrated by the lowess line on the plot.
Patella Lead Levels and Neurobehavioral and Peripheral Nervous System Measures
Next, the four linear regression models were evaluated with ranked patella. For "model 1," coefficients for the ranked patella term were neg- ative and had associated P values Յ0.10 for two of 14 neurobehavioral measures, one PNS measure, and the symptom score (data not shown), providing only limited evidence of an association between patella lead and neurobehavioral or PNS function. Associations with patella lead were dramatically reduced after addition of blood lead to the models. There was an association with only the symptom score (model 2, data not shown). After addition of job duration and removal of blood lead (model 3, data presented in Table 3 under "ranked patella" column), there were associations (at a significance level Ͻ0.10) of patella lead with five tests in the domain of manual dexterity, the PNS sensory vibration threshold (dominant great toe), and Center for Epidemiologic Studies-Depression (CES-D). All beta coefficients were negative, indicating an adverse effect. After addition of blood lead to model three, associations with patella lead were fewer and involved only the PNS sensory function and neuropsychiatric status as measured by symptoms (data not shown); only two associations remained significant at a level of P Ͻ 0.10. §All models controlled for age, gender, education, and job duration. Models of the PNS sensory measures also included height; models of the PNS strength measures also included body mass index. All outcomes have been standardized, so a negative ␤ coefficient indicates that performance was worse with increasing lead biomarker levels.
Ranked values obtained by percentile ranking of the lead biomarkers. ␤ coefficients represent the change in neurobehavioral test score for a one-percentile change in the rank of the biomarker. ¶Patella lead and blood lead measured at visit three. **Tibia lead measurements taken at visit two (only includes values for those subjects completing visit three). † †Significant predictor of better performance. ‡ ‡Vibration unit ϭ 1/2 (amplitude ͓͔) 2 . SE indicates standard error; SD, standard deviation; MSD, mean square deviation; CES-D, Center for Epidemiologic Studies-Depression scale; PNS, peripheral nervous system.
Comparison of Lead Biomarkers
Comparison of the associations of patella lead, tibia lead, and blood lead (modeled as ranked values) with neurobehavioral test scores were evaluated in terms of significance, magnitude, and consistency of the associations within and across domains. As seen in Table 3 , tibia lead was significantly associated (P Ͻ 0.10) with worse performance on 11 tests. Blood lead and patella lead were both associated with worse performance on seven of the tests. When evaluating consistency within and across domains, patella lead behaved similarly to both blood lead and tibia lead in the domains of manual dexterity, executive abilities, neuropsychiatric status, and PNS sensory function. Tibia lead was more consistent in the domain of executive abilities and, unlike patella and blood lead, also was associated with poorer performance in the domain of psychomotor speed. The magnitude for a 1% change in ranked patella estimates was generally smaller than those for blood and tibia lead.
Discussion
In this study of neurobehavioral and PNS outcomes, in models controlling for job duration, we observed consistent associations with patella lead in the areas of manual dexterity, peripheral vibration threshold, and CES-D. In comparing the three lead biomarkers, we evaluated significance, magnitude, and consistency of the associations within and across domains. We concluded that inclusion of patella lead in the study, with blood lead and tibia lead, did not provide additional information useful to causal inference. The contrasting associations suggest that both recent and cumulative dose are important predictors of neurobehavioral test scores, but patella lead, which is measured with considerable additional time and cost, was of no apparent marginal benefit.
To date, six studies have examined relations of trabecular bone lead levelswithcognitivefunction.Thestudies have differed widely in design, trabecular bone measurement site, study population, sample size, covariates, and neurobehavioral assessment (Table 1) . 10 -12,15-17 All of the studies compared trabecular bone lead measures with blood lead and all but one 10 with tibia lead. Four of the six studies were nonoccupational and all of these used data from the Veterans Administration Normative Aging Study. 12, [15] [16] [17] In two of the nonoccupational studies, patella lead was found to be a better predictor of psychiatric symptoms 15 and longitudinal decline in Mini-Mental Status Examination scores. 17 Our finding that blood lead was more strongly associated with neurobehavioral test scores than patella lead, as evidenced by the magnitude of the regression coefficients (Table 3) , is consistent with those of Hänninen et al, 11 an occupationally exposed cohort, and Payton et al, 12 an environmentally exposed population. Hänninen et al similarly found significant associations of trabecular bone lead with psychiatric symptoms.
11
In conclusion, in this large cohort of current and former lead workers, we observed associations of patella lead levels with neurobehavioral test scores in the domains of manual dexterity, sensory PNS function, and psychiatric symptoms. In conjunction with our other cross-sectional and longitudinal observations in this population, 18, 19 the data suggest that lead influences neurobehavioral test scores as a function of both recent and cumulative dose, but measurement of patella lead did not aid in causal inference in this study. Although we believe the three lead biomarkers are reflective of different dose periods, in vivo pools, and kinetics, our data do not suggest that patella lead behaves significantly differently than blood and tibia lead in its associations with nervous system outcomes. The generally weaker associations with patella lead may suggest that bioavailable bone lead was less important to cognitive function in these workers than was the acute effects of recent dose, as estimated by blood lead, and the chronic effects of cumulative dose, as estimated by tibia lead. It is possible that individual neurobehavioral tests may be differentially associated with the different lead biomarkers for biologic or other reasons; however, when evaluating associations with neurobehavioral testing, it is the domains that are relevant to interpretation and the associations of patella lead were consistent with the other biomarkers and did not provide additional information. It is also possible that the weaker relations with patella lead were due to the measurement error in patella lead as previously reported. 26 
